76-90 of 447
An Assessment of Automated Insulin Delivery Systems for T1D
Diabetes DiscourseAn Assessment of Automated Insulin Delivery Systems for T1D
John Buse, MD, PhD
Martin de Bock, PhD FRACP
A Look at Comprehensive Telehealth for PPDM
Diabetes DiscourseA Look at Comprehensive Telehealth for PPDM
John Buse, MD, PhD
Matthew Crowley, MD
SNAP, Food Insecurity, & Healthcare Spending: What Do We Need to Know?
Diabetes DiscourseSNAP, Food Insecurity, & Healthcare Spending: What Do We Need to Know?
John Buse, MD, PhD
Seth Berkowitz, MD, MPH
Getting to Know GRADE: A Comparative Study of T2D Treatment
Diabetes DiscourseGetting to Know GRADE: A Comparative Study of T2D Treatment
John Buse, MD, PhD
Ashok Balasubramanyam, MD
Exploring Precision Medicine in the Treatment of Diabetes
Diabetes DiscourseExploring Precision Medicine in the Treatment of Diabetes
John Buse, MD, PhD
Jose C. Florez, MD, PhD
Can Generic Drugs Be Repurposed for COVID-19 Treatment?
Diabetes DiscourseCan Generic Drugs Be Repurposed for COVID-19 Treatment?
John Buse, MD, PhD
Carolyn Bramante
- advertisement
A Fight Against Obesity: Evaluating Clinical Data from the SURMOUNT-1 Trial
Diabetes DiscourseA Fight Against Obesity: Evaluating Clinical Data from the SURMOUNT-1 Trial
John Buse, MD, PhD
Ania Jastreboff, MD, PhD
Heart Failure Consensus Report: A Review of ADA Recommendations
Diabetes DiscourseHeart Failure Consensus Report: A Review of ADA Recommendations
John Buse, MD, PhD
Rodica Pop-Busui, MD, PhD
Exploring AACE Updates on the Management of NAFLD & NASH
Diabetes DiscourseExploring AACE Updates on the Management of NAFLD & NASH
John Buse, MD, PhD
Kenneth Cusi, MD, FACP, FACE
The IRIS Trial: Reviewing Results & Taking a Look at Pioglitazone
Diabetes DiscourseThe IRIS Trial: Reviewing Results & Taking a Look at Pioglitazone
John Buse, MD, PhD
David Spence, MD
Highlights from the Final Days of the American Diabetes Association's 82nd Scientific Sessions
ADA Action CenterHighlights from the Final Days of the American Diabetes Association's 82nd Scientific Sessions
Highlights From Day 3 of the American Diabetes Association's 82nd Scientific Sessions
ADA Action CenterHighlights From Day 3 of the American Diabetes Association's 82nd Scientific Sessions
- advertisement
Tirzepatides & Therapeutic Inertia: Highlights from ADA
ADA Action CenterTirzepatides & Therapeutic Inertia: Highlights from ADA
Carol Wysham
Updates From Day 2 of the American Diabetes Association's 82nd Scientific Sessions
ADA Action CenterUpdates From Day 2 of the American Diabetes Association's 82nd Scientific Sessions
Recapping Day 1 of the American Diabetes Association's 82nd Scientific Sessions
ADA Action CenterRecapping Day 1 of the American Diabetes Association's 82nd Scientific Sessions
